Telix Pharmaceuticals (TLX) Total Debt (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Total Debt for 3 consecutive years, with $405.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Debt rose 8.5% year-over-year to $405.0 million; the TTM figure through Dec 2025 stood at $405.0 million (up 8.5% YoY), while the FY2025 annual figure was $405.0 million, up 8.5% from the prior year.
• Total Debt climbed to $405.0 million in Q4 2025 per TLX's latest filing, from $373.3 million in the prior quarter.
• Across five years, Total Debt topped out at $405.0 million in Q4 2025 and bottomed at $6.0 million in Q4 2023.
• Historically, Total Debt has averaged $261.4 million across 3 years, with a median of $373.3 million in 2024.
• Annual changes were most pronounced in 2024 — Total Debt soared 6151.08% — and 2025, when it rose 8.5%.
• Telix Pharmaceuticals' Total Debt stood at $6.0 million in 2023, then jumped by 6151.08% to $373.3 million in 2024, then increased by 8.5% to $405.0 million in 2025.
• Business Quant data shows TLX's Total Debt at $405.0 million in Q4 2025, $373.3 million in Q4 2024, and $6.0 million in Q4 2023.